HER2 status-Positive - Page 2 of 4 Posts on Medivizor

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

Posted by Medivizor on Oct 23, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...

The outcomes of trastuzumab emtansine in patients with brain metastasis from HER2-positive breast cancer

Posted by Medivizor on Jul 19, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated the effects of trastuzumab emtansine (T-DM1; Kadcyla) to treat patients with brain metastasis (BM) from HER2-positive metastatic breast cancer (mBC). The main finding was that T-DM1 was safe and effective in such patients. Some background HER-2 positive mBC cells have an excess of the HER-2 protein. Such cancers...

Long-term outcomes of pertuzumab added to trastuzumab and docetaxel treatment for patients with advanced HER2-positive breast cancer

Posted by Medivizor on Apr 7, 2020 in Breast cancer | 0 comments

In a nutshell This study looked at whether pertuzumab (Perjeta) benefits patients with metastatic HER2-positive breast cancer when added to trastuzumab (Herceptin) and docetaxel (Taxotere) treatment. They found that adding pertuzumab improved long-term patient outcomes. Some background Breast cancer can now be tested for some of the signals involved...

Comparing 6- and 12-month trastuzumab treatment after surgery for early breast cancer

Posted by Medivizor on Oct 26, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the outcomes for patients with early breast cancer who received 6- or 12-months trastuzumab after surgery. This study concluded that the standard duration of trastuzumab after surgery should remain 12 months. Some background Trastuzumab (Herceptin) is a targeted...

Searching for patients with early-stage HER2+ breast cancer to trial a new treatment regime

Posted by Medivizor on Apr 24, 2019 in Breast cancer | 0 comments

In a nutshell This study will examine how safe and effective the medication atezolizumab (Tecentriq) is in combination with other anti-cancer medicines for treating early stage HER2+ breast cancer. The main outcome that will be measured is how many patients completely respond to treatment, with no trace of the cancer remaining. The details...

The effects of neratinib on quality of life in women with early-stage breast cancer

Posted by Medivizor on Mar 18, 2019 in Breast cancer | 0 comments

In a nutshell This study examined the effects of neratinib (Nerlynx) in women with early-stage breast cancer. This study found that treatment with neratinib decreased the quality of life of these patients during the first month of treatment due to side effects. Some background Between 15 and 20% of patients diagnosed with...

Searching for patients with breast cancer to trial a new drug

Posted by Medivizor on Mar 12, 2019 in Breast cancer | 0 comments

In a nutshell This trial aims to find out how well a new drug (DS-8201a) works on breast cancer that expresses low levels of the HER2 receptor and is not able to be operated on. The main outcome that will be measured is survival without cancer growing or spreading. The details The drug DS-8201a is a new anti-cancer drug that works against breast...

Searching for patients with HER2 positive breast cancer that has spread to trial a new treatment

Posted by Medivizor on Feb 23, 2019 in Breast cancer | 0 comments

In a nutshell This trial aims to see if combining two medications, T-DM1 (Kadcycla) and palbociclib (Ibrance) is better than just using T-DM1 in treating HER2+ breast cancer that has spread. The main outcome that will be measured is survival without the cancer growing or spreading. The study is being conducted in Arizona, the United States. The...

Treatment time with trastuzumab in HER-2 positive breast cancer

Posted by Medivizor on Dec 23, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if shortening treatment for HER2-positive breast cancer with trastuzumab (Herceptin) from 1 year to 9 weeks would make the treatment less effective. The study found that treatment for nine weeks was not less effective than treatment for 1 year. Some background HER-2 positive breast cancer is a type of...

Adding pertuzumab to treatment in breast cancer

Posted by Medivizor on Dec 4, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out which treatment is better for breast cancer, chemotherapy plus trastuzumab (Herceptin) and surgery, or pertuzumab (Perjeta), and chemotherapy plus trastuzumab (Herceptin) and surgery. The study found that adding pertuzumab to the standard treatment worked better to completely remove all signs of cancer compared...

Comparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer

Posted by Medivizor on Jul 2, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to compare lapatinib (Tykerb) and trastuzumab (Herceptin) in patients with HER-2 receptor positive breast cancer. This study found that in patients with hormone receptor-positive tumors, use of lapatinib for 6 months, followed by trastuzumab for 12 months significantly improved survival...

Are two HER-2 medications combined with hormone therapy effective?

Posted by Medivizor on May 6, 2018 in Breast cancer | 0 comments

In a nutshell This trial aimed to evaluate the use of a second treatment targeting HER-2 in a group of patients that had HER-2, HR positive metastatic breast cancer. This study found that patients treated with dual HER-2 medications with hormone therapy had a superior progression free survival as compared to those using one medication...

HER2 status-Positive Posts on Medivizor

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

The outcomes of trastuzumab emtansine in patients with brain metastasis from HER2-positive breast cancer

Long-term outcomes of pertuzumab added to trastuzumab and docetaxel treatment for patients with advanced HER2-positive breast cancer

Comparing 6- and 12-month trastuzumab treatment after surgery for early breast cancer

Searching for patients with early-stage HER2+ breast cancer to trial a new treatment regime

The effects of neratinib on quality of life in women with early-stage breast cancer

Searching for patients with breast cancer to trial a new drug

Searching for patients with HER2 positive breast cancer that has spread to trial a new treatment

Treatment time with trastuzumab in HER-2 positive breast cancer

Adding pertuzumab to treatment in breast cancer

Comparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer

Are two HER-2 medications combined with hormone therapy effective?

Categories

Recent Posts

Archives

HER2 status-Positive Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email